Results of a phase III study presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna reveal that using crizotinib as a targeted therapy may be more effective for patients with advanced ALK positive lung cancer compared to standard chemotherapy.
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are found in about 5% of all lung cancers. In previous uncontrolled studies, crizotinib has been shown to induce significant clinical responses in patients with advanced ALK-positive lung cancer....
Results of a phase III study presented at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna reveal that using crizotinib as a targeted therapy may be more effective for patients with advanced ALK positive lung cancer compared to standard chemotherapy.
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are found in about 5% of all lung cancers. In previous uncontrolled studies, crizotinib has been shown to induce significant clinical responses in patients with advanced ALK-positive lung cancer....